Inhibiting eicosanoid degradation exerts antifibrotic effects in a pulmonary fibrosis mouse model and human tissue.
Idiopathic pulmonary fibrosis (IPF) is a disease with high 5-year mortality and few therapeutic options. Prostaglandin (PG)E2 exhibits antifibrotic properties and is reduced in broncho-alveolar lavage from IPF patients. 15-prostaglandin dehydrogenase (15-PGDH) is the key enzyme in PGE2 metabolism under the control of transforming growth factor-beta and microRNA 218. We investigated the expression of 15-PGDH in IPF and the therapeutic potential of a specific inhibitor of this enzyme in a mouse model and human tissue. In vitro studies, including fibrocyte differentiation, regulation of 15-PGDH, RT-PCR and Western blot were performed using peripheral blood from healthy donors and IPF patients and A549 cells. IHC, IF, 15-PGDH activity assays and ISH as well as ex vivo IPF tissue culture experiments were done using healthy donor and IPF patient lungs. Therapeutic effects of 15-PGDH inhibition were studied in the bleomycin mouse model of pulmonary fibrosis. We demonstrate that 15-PGDH shows areas of increased expression in IPF patients. Inhibition of this enzyme increases PGE2 levels and reduces collagen production in IPF precision cut lung slices and in the bleomycin model. Inhibitor-treated mice show amelioration of lung function, decreased alveolar epithelial cell apoptosis and fibroblast proliferation. Pulmonary fibrocyte accumulation is also decreased by inhibitor treatment in mice, similar to PGE2 that inhibits fibrocyte differentiation from blood of healthy donors and IPF patients. Finally, microRNA 218-5p, which is downregulated in IPF patients, suppressed 15-PGDH expression in vivo and in vitro. These findings highlight the role of 15-PGDH in IPF and suggest 15-PGDH inhibition as a promising therapeutic approach.